29.45
price up icon3.26%   0.93
after-market After Hours: 29.45
loading
Avidity Biosciences Inc stock is traded at $29.45, with a volume of 1.75M. It is up +3.26% in the last 24 hours and down -4.51% over the past month. Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
See More
Previous Close:
$28.52
Open:
$29.07
24h Volume:
1.75M
Relative Volume:
1.19
Market Cap:
$3.21B
Revenue:
$10.12M
Net Income/Loss:
$-280.49M
P/E Ratio:
-10.19
EPS:
-2.89
Net Cash Flow:
$-188.51M
1W Performance:
+10.38%
1M Performance:
-4.51%
6M Performance:
-37.84%
1Y Performance:
+21.90%
1-Day Range:
Value
$28.15
$29.73
1-Week Range:
Value
$25.28
$29.73
52-Week Range:
Value
$21.51
$56.00

Avidity Biosciences Inc Stock (RNA) Company Profile

Name
Name
Avidity Biosciences Inc
Name
Phone
858-401-7900
Name
Address
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Name
Employee
391
Name
Twitter
Name
Next Earnings Date
2024-12-07
Name
Latest SEC Filings
Name
RNA's Discussions on Twitter

Compare RNA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
RNA
Avidity Biosciences Inc
29.45 3.21B 10.12M -280.49M -188.51M -2.89
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
490.47 128.67B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
585.49 60.99B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
599.87 36.96B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
236.75 29.89B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
252.77 25.74B 3.81B -644.79M -669.77M -6.24

Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-13-25 Initiated Citigroup Buy
Mar-12-25 Initiated BMO Capital Markets Outperform
Mar-07-25 Initiated Scotiabank Sector Outperform
Dec-20-24 Initiated H.C. Wainwright Buy
Nov-26-24 Initiated RBC Capital Mkts Outperform
Sep-24-24 Initiated Goldman Buy
Aug-28-24 Initiated Barclays Overweight
May-03-24 Initiated BofA Securities Buy
Mar-14-24 Initiated Cantor Fitzgerald Overweight
May-22-23 Upgrade Evercore ISI In-line → Outperform
Mar-31-23 Downgrade Evercore ISI Outperform → In-line
Jul-20-22 Initiated Chardan Capital Markets Buy
Jul-12-22 Initiated Raymond James Strong Buy
Sep-07-21 Initiated Evercore ISI Outperform
Jun-17-21 Initiated Needham Buy
Apr-26-21 Resumed Credit Suisse Outperform
Jul-07-20 Initiated Cowen Outperform
Jul-07-20 Initiated Credit Suisse Outperform
Jul-07-20 Initiated SVB Leerink Outperform
Jul-07-20 Initiated Wells Fargo Overweight
View All

Avidity Biosciences Inc Stock (RNA) Latest News

pulisher
05:29 AM

Avidity Biosciences' RNA Drug for DM1 Gains Orphan Status in Jap - GuruFocus

05:29 AM
pulisher
Apr 21, 2025

Avidity Biosciences Expands Team with 33 New Hires, Grants $10M+ in Equity Incentives - Stock Titan

Apr 21, 2025
pulisher
Apr 18, 2025

Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025 (PR Newswire) - Aktiellt

Apr 18, 2025
pulisher
Apr 09, 2025

Beyond The Numbers: 13 Analysts Discuss Avidity Biosciences Stock - Benzinga

Apr 09, 2025
pulisher
Apr 08, 2025

Japan grants Avidity’s DM1 drug Orphan status By Investing.com - Investing.com South Africa

Apr 08, 2025
pulisher
Apr 08, 2025

Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1 - StreetInsider

Apr 08, 2025
pulisher
Apr 08, 2025

Avidity Biosciences Receives Orphan Drug Designation in Japan fo - GuruFocus

Apr 08, 2025
pulisher
Apr 08, 2025

Avidity Says Japan Grants Orphan Drug Status to Del-Desiran for Myotonic Dystrophy Type 1 - marketscreener.com

Apr 08, 2025
pulisher
Apr 08, 2025

Japan grants Avidity's DM1 drug Orphan status By Investing.com - Investing.com India

Apr 08, 2025
pulisher
Apr 08, 2025

Japan grants Avidity's DM1 drug Orphan status - Investing.com

Apr 08, 2025
pulisher
Apr 08, 2025

Avidity Biosciences Receives Orphan Drug Designation In Japan For Delpacibart Etedesiran - MarketScreener

Apr 08, 2025
pulisher
Apr 06, 2025

Avidity Biosciences chief program officer sells shares worth $206,799 - MSN

Apr 06, 2025
pulisher
Apr 06, 2025

Avidity Biosciences CFO sells $93,985 in stock - MSN

Apr 06, 2025
pulisher
Apr 05, 2025

Avidity Biosciences (RNA): Among Unstoppable Stocks That Could Double Your Money - MSN

Apr 05, 2025
pulisher
Apr 03, 2025

Avidity Biosciences’ chief program officer sells $163k in stock - Investing.com India

Apr 03, 2025
pulisher
Apr 03, 2025

Avidity Biosciences’ chief program officer sells $163k in stock By Investing.com - Investing.com UK

Apr 03, 2025
pulisher
Apr 03, 2025

Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock? - Nasdaq

Apr 03, 2025
pulisher
Apr 02, 2025

When the Price of (RNA) Talks, People Listen - news.stocktradersdaily.com

Apr 02, 2025
pulisher
Apr 02, 2025

Avidity Biosciences : to Present at the Virtual Chardan 4th Annual Genetic Medicines Conference 2020 - marketscreener.com

Apr 02, 2025
pulisher
Apr 01, 2025

Avidity Biosciences to Participate in Upcoming Investor Conference - StreetInsider

Apr 01, 2025
pulisher
Mar 31, 2025

Avidity Biosciences’s SWOT analysis: stock poised for growth amid clinical progress - Investing.com India

Mar 31, 2025
pulisher
Mar 31, 2025

Cantor Fitzgerald maintains $96 target on Avidity Biosciences stock - Investing.com Australia

Mar 31, 2025
pulisher
Mar 31, 2025

Cantor Fitzgerald maintains $96 target on Avidity Biosciences stock By Investing.com - Investing.com Canada

Mar 31, 2025
pulisher
Mar 31, 2025

Avidity Biosciences’s SWOT analysis: stock poised for growth amid clinical progress By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 31, 2025

Avidity Completes Enrollment in Del-brax Trial's Biomarker Group for Facioscapulohumeral Muscular Dystrophy - MarketScreener

Mar 31, 2025
pulisher
Mar 31, 2025

Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy - StreetInsider

Mar 31, 2025
pulisher
Mar 31, 2025

Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy – Company AnnouncementFT.com - Financial Times

Mar 31, 2025
pulisher
Mar 30, 2025

11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey

Mar 30, 2025
pulisher
Mar 29, 2025

EFG Asset Management North America Corp. Purchases 58,198 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat

Mar 29, 2025
pulisher
Mar 26, 2025

The Risk/Reward Of Avidity Biosciences And Its 2 Promising Programs (NASDAQ:RNA) - Seeking Alpha

Mar 26, 2025
pulisher
Mar 22, 2025

Avidity Biosciences chief scientific officer sells $365,867 in stock By Investing.com - Investing.com Australia

Mar 22, 2025
pulisher
Mar 22, 2025

Avidity Biosciences CFO Michael MacLean sells $246,424 in stock By Investing.com - Investing.com Australia

Mar 22, 2025
pulisher
Mar 22, 2025

Avidity Biosciences Inc Stock: Leadership Sells Shares Amid Clinical Success - Sharewise

Mar 22, 2025
pulisher
Mar 21, 2025

Avidity Biosciences chief HR officer sells $241,583 in stock By Investing.com - Investing.com Australia

Mar 21, 2025
pulisher
Mar 21, 2025

Avidity Biosciences chief HR officer sells $241,583 in stock - Investing.com India

Mar 21, 2025
pulisher
Mar 21, 2025

Avidity Biosciences CEO Sarah Boyce sells $979,563 in stock - Investing.com India

Mar 21, 2025
pulisher
Mar 21, 2025

Avidity Biosciences CEO Sarah Boyce sells $979,563 in stock By Investing.com - Investing.com South Africa

Mar 21, 2025
pulisher
Mar 21, 2025

Avidity Biosciences chief scientific officer sells $365,867 in stock - Investing.com

Mar 21, 2025
pulisher
Mar 21, 2025

Avidity Biosciences chief medical officer sells $297,490 in stock - Investing.com

Mar 21, 2025
pulisher
Mar 21, 2025

Avidity Biosciences Executives Sell Shares for Tax Obligations - TradingView

Mar 21, 2025
pulisher
Mar 21, 2025

Avidity Biosciences Executives Sell Shares to Cover Tax Obligations - TradingView

Mar 21, 2025
pulisher
Mar 21, 2025

Avidity Biosciences announces inducement grants under Nasdaq listing rule 5635(C)(4) - Marketscreener.com

Mar 21, 2025
pulisher
Mar 21, 2025

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Kilgore News Herald

Mar 21, 2025
pulisher
Mar 19, 2025

H.C. Wainwright maintains $72 target on Avidity Biosciences stock By Investing.com - Investing.com Canada

Mar 19, 2025
pulisher
Mar 18, 2025

Forecasting The Future: 13 Analyst Projections For Avidity Biosciences - Benzinga

Mar 18, 2025
pulisher
Mar 18, 2025

Avidity’s del-zota elicits 25% increase in dystrophin in DMD patients - Yahoo Finance

Mar 18, 2025
pulisher
Mar 18, 2025

New Duchenne Results Put Avidity On Course For Filing - insights.citeline.com

Mar 18, 2025
pulisher
Mar 18, 2025

Avidity Biosciences reports progress in DMD treatment trial By Investing.com - Investing.com Australia

Mar 18, 2025

Avidity Biosciences Inc Stock (RNA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.27
price up icon 1.00%
$71.24
price up icon 2.49%
$32.19
price up icon 0.00%
$27.35
price up icon 8.45%
$104.68
price up icon 2.82%
biotechnology ONC
$252.77
price up icon 10.27%
Cap:     |  Volume (24h):